S. Reigadas

发表

Riboproteomic analysis of polypeptides interacting with the internal ribosome‐entry site element of foot‐and‐mouth disease viral RNA

E. Martínez-Salas, A. Pacheco, S. Reigadas, 2008, Proteomics.

A promoter activity is present in the DNA sequence corresponding to the hepatitis C virus 5' UTR.

C. Staedel, S. Reigadas, A. Cahour, 2003, Nucleic acids research.

K65R in Subtype C HIV-1 Isolates from Patients Failing on a First-Line Regimen Including d4T or AZT: Comparison of Sanger and UDP Sequencing Data

H. Fleury, S. Reigadas, P. Recordon-Pinson, 2012, PloS one.

Risk of Virological Failure in HIV-1-Infected Patients Experiencing Low-Level Viraemia under Active Antiretroviral Therapy (ANRS C03 Cohort Study)

P. Morlat, E. Lazaro, G. Chêne, 2015, Antiviral therapy.

A functional selection of viral genetic elements in cultured cells to identify hepatitis C virus RNA translation inhibitors†

J. Toulmé, C. Wychowski, C. Staedel, 2008, Nucleic acids research.

HCV RNA-dependent RNA polymerase replicates in vitro the 3' terminal region of the minus-strand viral RNA more efficiently than the 3' terminal region of the plus RNA.

M. Castroviejo, S. Reigadas, M. Ventura, 2001, European journal of biochemistry.

Specific interference between two unrelated internal ribosome entry site elements impairs translation efficiency

E. Martínez-Salas, Jorge Ramajo, A. Pacheco, 2005, FEBS letters.

Wildo Navegantes de Araújo, M. Ziol, V. Paradis, 2019, AIDS and Behavior.

Quantitation of HIV-1 RNA in dried blood and plasma spots.

H. Fleury, S. Reigadas, V. Aurillac-Lavignolle, 2009, Journal of virological methods.

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

M. Ziol, C. Delaugerre, C. Katlama, 2022, AIDS Research and Therapy.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma

V. Calvez, C. Delaugerre, S. Yerly, 2017, The Journal of antimicrobial chemotherapy.

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

L. Stuyver, B. Masquelier, H. Fleury, 2010, PloS one.

Anti‐HIV Activity of Steric Block Oligonucleotides

A. Lever, J. Toulmé, S. Reigadas, 2006, Annals of the New York Academy of Sciences.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

V. Calvez, C. Delaugerre, S. Yerly, 2015, The Journal of antimicrobial chemotherapy.

An oligonucleotide complementary to the SL-B1 domain in the 3'-end of the minus-strand RNA of the hepatitis C virus inhibits in vitro initiation of RNA synthesis by the viral polymerase.

M. Andreola, S. Reigadas, L. Tarrago-Litvak, 2003, Virology.

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.

B. Masquelier, H. Fleury, O. Cosnefroy, 2010, The Journal of antimicrobial chemotherapy.

Viremia Copy-Years as a Predictive Marker of All-Cause Mortality in HIV-1–Infected Patients Initiating a Protease Inhibitor–Containing Antiretroviral Treatment

B. Hoen, J. Cassuto, F. Raffi, 2015, Journal of acquired immune deficiency syndromes.

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

V. Calvez, C. Charpentier, C. Delaugerre, 2015, The Journal of antimicrobial chemotherapy.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

B. Masquelier, D. Breilh, D. Neau, 2010, The Journal of antimicrobial chemotherapy.

Comparative Studies of Tricyclo-DNA- and LNA-Containing Oligonucleotides as Inhibitors of HIV-1 Gene Expression

J. Toulmé, D. Ittig, C. Leumann, 2007, Nucleosides, nucleotides & nucleic acids.

Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity.

J. Toulmé, D. Ittig, C. Leumann, 2007, Oligonucleotides.

Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy

V. de Lédinghen, H. Fleury, M. Kann, 2013, Antiviral therapy.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

V. Calvez, C. Charpentier, C. Delaugerre, 2017, The Journal of antimicrobial chemotherapy.

Aptamers targeted to an RNA hairpin show improved specificity compared to that of complementary oligonucleotides.

C. Di Primo, J. Toulmé, F. Darfeuille, 2006, Biochemistry.

Stimulation of the Human RAD51 Nucleofilament Restricts HIV-1 Integration In Vitro and in Infected Cells

P. Sung, H. Fleury, E. Le Cam, 2011, Journal of Virology.

Variability and recombination of clinical human cytomegalovirus strains from transplantation recipients.

J. Velly, H. Fleury, C. Dromer, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hepatitis C virus (HCV) protease variability and anti‐HCV protease inhibitor resistance in HIV/HCV‐coinfected patients

D. Neau, J. Ragnaud, M. Dupon, 2011, HIV Medicine.

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure

B. Masquelier, D. Neau, P. Morlat, 2014, PloS one.

Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study

M. Wainberg, J. Routy, H. Fleury, 2014, PLoS ONE.

Resistance Mutations and CTL Epitopes in Archived HIV-1 DNA of Patients on Antiviral Treatment: Toward a New Concept of Vaccine

D. Neau, H. Fleury, E. Lazaro, 2013, PloS one.

Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.

H. Fleury, P. Bellecave, S. Reigadas, 2014, AIDS research and human retroviruses.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).

M. Ziol, V. Paradis, C. Delaugerre, 2020, Journal of hepatology.

Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.

C. Charpentier, B. Masquelier, F. Raffi, 2011, The Journal of antimicrobial chemotherapy.

Activation of GCN2 upon HIV-1 infection and inhibition of translation

H. Fleury, A. Jaspart, C. Calmels, 2013, Cellular and Molecular Life Sciences.

Diagnostic Accuracy of Dried Plasma Spot Specimens for HIV-1 Viral Load Testing: A Systematic Review and Meta-analysis

Ingrid A. Beck, Y. Fong, J. Nelson, 2021, Journal of acquired immune deficiency syndromes.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activation of GCN2 upon HIV-1 infection and inhibition of translation

H. Fleury, A. Jaspart, C. Calmels, 2013, Cellular and Molecular Life Sciences.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration

V. Parissi, M. Andreola, S. Reigadas, 2011, Antiviral therapy.

Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A

M. Laguerre, B. Masquelier, D. Neau, 2011, Antimicrobial Agents and Chemotherapy.

Structure analysis of HIV-1 IN Y143C/R Raltegravir resistance mutation in association

C. Calmels, H. Fleury, M. Laguerre, 2011 .

Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort

M. Ziol, C. Delaugerre, C. Katlama, 2020 .

Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA.

J. Toulmé, P. Herdewijn, A. Van Aerschot, 2005, Biochemistry.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

S. Yerly, B. Masquelier, H. Fleury, 2013, The Journal of antimicrobial chemotherapy.

Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

M. Ziol, C. Delaugerre, C. Katlama, 2022, JHEP reports : innovation in hepatology.

Systematic screening of LNA/2′‐O‐methyl chimeric derivatives of a TAR RNA aptamer

C. Di Primo, J. Toulmé, S. Reigadas, 2007, FEBS letters.

Endogenous Expression of an Anti-TAR Aptamer Reduces HIV-1 Replication

J. Toulmé, J. Rossi, D. Castanotto, 2006, RNA biology.